Treatment Response and the quality of life of ch. Hepatitis C patients

Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication; the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: · Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. · Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. · Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models.